Related Experiment Videos
Long-term results after bronchial sleeve resection
1Department of Surgery, University Hospital of Antwerp, Edegem.
Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie
|July 25, 2000
Summary
Bronchial sleeve resections can save lung tissue in lung cancer surgery. However, long-term survival heavily depends on lymph node status (N stage), with advanced stages requiring adjuvant therapy.
Area of Science:
- Thoracic Surgery
- Surgical Oncology
- Pulmonary Medicine
Background:
- Bronchial sleeve resection preserves lung parenchyma in centrally located bronchogenic carcinomas.
- This technique allows for oncologically sound operations while minimizing lung tissue loss.
- Long-term survival data after bronchial sleeve resection, particularly concerning nodal status, remain controversial.
Purpose of the Study:
- To evaluate the long-term survival outcomes of patients undergoing bronchial sleeve resection for bronchogenic tumors.
- To identify significant prognostic factors influencing survival after this procedure.
- To provide evidence-based recommendations for adjuvant treatment strategies.
Main Methods:
- A retrospective analysis of 145 patients who underwent bronchial sleeve resection.
- Univariate and multivariate analyses, including Cox regression, were performed to assess survival predictors.
- Long-term follow-up was updated until 1999, ensuring a minimum of 10 years for surviving patients.
Main Results:
- Overall 5, 10, and 15-year survival rates were 45%, 35%, and 23%, respectively.
- Survival rates significantly differed based on nodal stage: N0 (62% at 5 yrs), N1 (29% at 5 yrs), and N2 (31% at 5 yrs).
- Nodal stage and patient age were identified as significant independent predictors of survival.
Conclusions:
- Bronchial sleeve resection offers a viable oncological option for lung cancer, but long-term survival is critically dependent on nodal involvement.
- Patients with N1 or N2 disease have significantly poorer prognoses and may benefit from adjuvant therapies.
- Adjuvant treatment should be strongly considered for patients with positive lymph nodes (N1/N2) to combat distant metastases and improve overall survival.